UCL  IRIS
Institutional Research Information Service
UCL Logo
Please report any queries concerning the funding data grouped in the sections named "Externally Awarded" or "Internally Disbursed" (shown on the profile page) to your Research Finance Administrator. Your can find your Research Finance Administrator at https://www.ucl.ac.uk/finance/research/rs-contacts.php by entering your department
Please report any queries concerning the student data shown on the profile page to:

Email: portico-services@ucl.ac.uk

Help Desk: http://www.ucl.ac.uk/ras/portico/helpdesk
Publication Detail
Cost-effectiveness analysis of endoscopic eradication therapy for treatment of high-grade dysplasia in Barrett's esophagus.
  • Publication Type:
    Journal article
  • Publication Sub Type:
    Evaluation Studies
  • Authors:
    Filby A, Taylor M, Lipman G, Lovat L, Haidry R
  • Publication date:
    07/2017
  • Pagination:
    425, 436
  • Journal:
    Journal of comparative effectiveness research
  • Volume:
    6
  • Issue:
    5
  • Medium:
    Print-Electronic
  • Status:
    Published
  • Print ISSN:
    2042-6305
  • Language:
    eng
  • Keywords:
    Humans, Barrett Esophagus, Catheter Ablation, Esophagoscopy, Treatment Outcome, Quality-Adjusted Life Years, Quality of Life, Aged, Aged, 80 and over, Middle Aged, Cost-Benefit Analysis, Health Care Costs
  • Addresses:
    York Health Economic Consortium (YHEC), Enterprise House, Innovation Way, University of York, York, UK.
Abstract
AIM:The aim was to evaluate the cost-effectiveness of endoscopic eradication therapy (EET) with combined endoscopic mucosal resection and radiofrequency ablation for the treatment of high-grade dysplasia (HGD) arising in patients with Barrett's esophagus compared with endoscopic surveillance alone in the UK. MATERIALS & METHODS:The cost-effectiveness model consisted of a decision tree and modified Markov model. A lifetime time horizon was adopted with the perspective of the UK healthcare system. RESULTS:The base case analysis estimates that EET for the treatment of HGD is cost-effective at a GB£20,000 cost-effectiveness threshold compared with providing surveillance alone for HGD patients (incremental cost-effectiveness ratio: GB£1272). CONCLUSION:EET is likely to be a cost-effective treatment strategy compared with surveillance alone in patients with HGD arising in Barrett's esophagus in the UK.
Publication data is maintained in RPS. Visit https://rps.ucl.ac.uk
 More search options
There are no UCL People associated with this publication
University College London - Gower Street - London - WC1E 6BT Tel:+44 (0)20 7679 2000

© UCL 1999–2011

Search by